EMA — authorised 8 February 2021
- Marketing authorisation holder: CELGENE EUROPE BV
- Status: approved
EMA authorised Inrebic on 8 February 2021
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA authorised it on 8 February 2021.
CELGENE EUROPE BV holds the EU marketing authorisation.